The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).
Francesco Sclafani
No relevant relationships to disclose
Clare Peckitt
No relevant relationships to disclose
David Cunningham
Consultant or Advisory Role - Amgen; Merck; Roche; Sanofi
Honoraria - Merck; Roche; Sanofi
Research Funding - Amgen; Merck Serono; Roche; Sanofi
Jessica Evans
No relevant relationships to disclose
Gina Brown
No relevant relationships to disclose
Josep Tabernero
Consultant or Advisory Role - Amgen; Merck; Roche; Sanofi
Bengt Glimelius
No relevant relationships to disclose
Andres Cervantes
Consultant or Advisory Role - Merck Serono; Roche
Honoraria - Merck Serono; Roche
Research Funding - Roche
Diana M. Tait
No relevant relationships to disclose
Andrew Wotherspoon
No relevant relationships to disclose
Janet Thomas
No relevant relationships to disclose
Jacqueline Rose Oates
No relevant relationships to disclose
Ian Chau
Consultant or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Lilly; Merck Serono; Novartis; Roche; Sanofi
Honoraria - Lilly; Sanofi ; Taiho Pharmaceutical
Research Funding - Merck Serono; Novartis; Roche; Sanofi